Home Tags Seagen

Tag: Seagen

Supplemental Biologics License Application for Tisotumab Vedotin Accepted for FDA Priority...

The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for tisotumab vedotin (Tivdak®; Genmab and Pfizer) for the treatment of patients with recurrent or metastatic cervical cancer.

Pfizer to Acquire Seagen for US $ 43 Billion

Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...

Zai Lab to Commercialize and Expand Patient Access to Tisotumab...

Zai Lab, a patient focused, global biopharma company committed to driving the next wave of healthcare innovation confirmed that it had signed an exclusive collaboration and...

Seagen and Sanofi Jointly Fund and Develop Antibody-drug Conjugate Programs

Seagen and Sanofi today confirmed that the companies have agreed to fund and commercialize the development of 3 antibody-drug Conjugates or ADCs designed to enhance...
Featured Image: Genmab's bioreactor laboratory. Photo Courtesy: 2020 Genmab.

Promising Preliminary Data on Tisotumab Vedotin in Patients with Head and...

Preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (Tivdak®; Seagen and Genmab) as a monotherapy in patients...
Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Japan Approves Enfortumab Vedotin for the Treatment of Advanced Urothelial Cancer

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved enfortumab vedotin (Padcev®; Astellas Pharma and Seagen) for the treatment of radically unresectable urothelial...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Remegen’s Disitamab Vedotin Attracts China’s largest-ever out-license Agreement at US $...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...
Exhibition booth Seattle Genetics - ASCO 2019 | Courtsey: Emila Duaerte / Sunvalley Communication

Enfortumab Vedotin Receives Regular Approval and an Expanded Indication for Locally...

The U.S. Food and Drug Administration (FDA) has granted regular approval for enfortumab vedotin-ejfv (Padcev®; Astellas Pharma and Seagen) while, at the same time,...
Seattle Genetics

Seattle Genetics Changes Corporate Name to Seagen

Seattle Genetics confirmed that it has changed it's corporate name to Seagen. According to a statement issued by the company, the new name reflects...
ASCO 50th Annual Meeting

Results from Phase I Trial with SGN-CD19A Shows Encouraging Anti-tumor Activity...

esults from an interim phase I clinical trial presented at the 50th Annual Meeting of the American Association of Clinical Oncology (ASCO), being held May 30 - June 3, 2014 in Chicago, Ill, shows that SGN-CD19A (Seattle Genetics, Inc, Bothell, WA 98021, USA), an antibody-drug conjugate or ADC in development for the treatment of B-cell malignancies, offers encouraging anti-tumore activity in patients with Non-Hodgkin Lymphoma (NHL).[1]

X